Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches

Schick, Jason; Ritchie, Raquel P.; Restini, Carolina Baraldi Araújo

doi:10.1177/1178223421995854

Cited by 37 publications

(25 citation statements)

References 493 publications

(454 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Except for surgery, the primary treatment modalities for breast cancer include radiation, chemotherapy, hormone-based therapies, or targeted therapy [ 78 , 79 ]. Indeed, conventional breast cancer therapies are associated with various adverse effects.…”

Section: Current State Of Clinical Evidence On the Effectiveness Of P...mentioning

confidence: 99%

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

et al. 2022

View full text Add to dashboard Cite

Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.

show abstract

Section: Current State Of Clinical Evidence On the Effectiveness Of P...mentioning

confidence: 99%

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The availability of relevant biomarkers used for BRCA patients’ classification, diagnosis and prognosis, and therapeutic options have increased significantly over the last decade [ 41 ]. Recent advances on next-generation sequencing (NGS) techniques, together with the decrease of NGS associated costs, have tremendously expanded the use of RNA-seq in clinical practice, leading to the production of a large amount of expression datasets whose information has still only in part decoded.…”

Section: Discussionmentioning

confidence: 99%

Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach

et al. 2021

View full text Add to dashboard Cite

Background: Cell-surface proteins have been widely used as diagnostic and prognostic markers in cancer research, and as targets for the development of anti-cancer agents. So far, very few attempts have been made to characterize the surfaceome of breast cancer patients, particularly in relation with the current molecular breast cancer (BRCA) classification. In this view, we developed a new computational method to infer cell-surface protein activities from transcriptomics data, termed “SURFACER”. Methods: Gene expression data from GTEx were used to build a normal breast network model as input to infer differential cell-surface proteins activity in BRCA tissue samples retrieved from TCGA vs. normal samples. Data were stratified according to the PAM50 transcriptional subtypes (Luminal A, Luminal B, HER2, Basal), while unsupervised clustering techniques were applied to define BRCA subtypes according to cell-surface proteins activity. Results: Our approach led to the identification of 213 PAM50 subtypes-specific deregulated surface genes and the definition of 5 BRCA subtypes, whose prognostic value was assessed by survival analysis, identifying a cell-surface activity configuration at increased risk. The value of the SURFACER method in BRCA genotyping was tested by evaluating the performance of 11 different machine learning classification algorithms. Conclusions: BRCA patients can be stratified into 5 surface activity-specific groups having the potential to identify subtype-specific actionable targets to design tailored targeted therapies, or for diagnostic purposes. SURFACER-defined subtypes show also a prognostic value, identifying surface-activity profiles at higher risk.

show abstract

“…Despite significant recent progress in diagnosis and therapy, breast cancer is still a serious problem for individuals and societies (reviewed in [ 1 ]). There are several reasons for this, including heterogeneity of cases and poorly understood mechanisms of breast cancer pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling

Błasiak

Chojnacki

Pawłowska

et al. 2022

IJMS

View full text Add to dashboard Cite

Dietary vitamin D3 has attracted wide interest as a natural compound for breast cancer prevention and therapy, supported by in vitro and animal studies. The exact mechanism of such action of vitamin D3 is unknown and may include several independent or partly dependent pathways. The active metabolite of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D, calcitriol), binds to the vitamin D receptor (VDR) and induces its translocation to the nucleus, where it transactivates a myriad of genes. Vitamin D3 is involved in the maintenance of a normal epigenetic profile whose disturbance may contribute to breast cancer. In general, the protective effect of vitamin D3 against breast cancer is underlined by inhibition of proliferation and migration, stimulation of differentiation and apoptosis, and inhibition of epithelial/mesenchymal transition in breast cells. Vitamin D3 may also inhibit the transformation of normal mammary progenitors into breast cancer stem cells that initiate and sustain the growth of breast tumors. As long noncoding RNAs (lncRNAs) play an important role in breast cancer pathogenesis, and the specific mechanisms underlying this role are poorly understood, we provided several arguments that vitamin D3/VDR may induce protective effects in breast cancer through modulation of lncRNAs that are important for breast cancer pathogenesis. The main lncRNAs candidates to mediate the protective effect of vitamin D3 in breast cancer are lncBCAS1-4_1, AFAP1 antisense RNA 1 (AFAP1-AS1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), long intergenic non-protein-coding RNA 511 (LINC00511), LINC00346, small nucleolar RNA host gene 6 (SNHG6), and SNHG16, but there is a rationale to explore several other lncRNAs.

show abstract

Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches

Cited by 37 publications

References 493 publications

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach

Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling

Contact Info

Product

Resources

About